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Abstract
Ibrahim, Ayon
Investigating the Use of Aptamers in Binding to the Human Follicle Stimulating
Hormone Receptor (hFSHR). Department of Biological Sciences, June 2013.
Advisor: Brian D. Cohen
Oral contraceptive pills use high doses of hormone to suppress the reproductive arm of the
endocrine system in women. However, these drugs can have harmful long term side effects such as
increased risk of stroke, heart attack, and breast cancer. Therefore, it has become an important public
health goal to look for alternative ways of providing contraception. Aptamers, oligonucleotides that
bind to specific molecules due to their unique 3-dimensional structure, are one alternative that has yet
to be explored. The goal of our research is to develop an RNA aptamer that will bind selectively to the
hFSHR. We first incubated a large pool containing random sequence oligonucleotides with wild type
HEK293 cells (which do not have hFSHR) as a counter-selection. Many of the RNA molecules bound
to the protein receptors on the cell surface. The unbound molecules were then incubated with HEK293
cells expressing the hFSHR. The oligonucleotides that bound to the hFSHR were eluted, isolated, and
then re-amplified. The process of selection was repeated while increasing stringency of binding each
time. We were able to successfully perform SELEX on our RNA pool at 4°C and 22°C. We also
conducted nanodrop experiments to confirm that our oligonucleotides are indeed binding specifically to
the hFSHR. We hope to continue refining our aptamer at higher temperatures such as 30°C and 37°C,
determine the exact nature of the oligonucleotide-protein binding complex, and eventually begin in vivo
trials to determine efficacy.
Introduction
The human follicle-stimulating hormone (FSH), also called follitropin, is a glycoprotein
secreted by the basophil cells in the anterior pituitary gland. It is a dimeric protein, consisting of an
alpha and a beta subunit, the latter of which interacts with the FSH receptor (FSHR). It is primarily the
pulsatile release of gonadotropin releasing hormone (GnRH), from the arctuate nucleus of the medial
basal hypothalamus, that causes the production and release of FSH from the gonadotropic cells of the
anterior pituitary. In males, follitropin binds to Sertoli cells in the testes, which induces the release of

inhibin, a protein hormone that negatively feed backs on the gonadotropes in the pituitary gland and
decreases the synthesis of follitropin, and activin, which also stimulates FSH production, in addition to
aromatase production and spermatogenesis [1]. A third hormone, follistatin, works with inhibin by
suppressing FSH gene expression. In females, follitropin binds to granulosa cells in ovaries, stimulating
the release of inhibin, as it does in the male. It also stimulates the production and release of
estrogen/estradiol, a steroid hormone that not only increases GnRH pulses from the hypothalamus but
also binds to the anterior pituitary and inhibits FSH production and release. Estrogen is crucial for
development of bone, muscle and secondary sex characteristics in the female [2]. Progesterone, a
steroid hormone released by theca cells in the ovary, acts upon the hypothalamus to lower GnRH
pulses. Progesterone's release is regulated by luteinizing hormone (LH), a dimeric protein similar in
structure to FSH that is also released by the basophil cells of the anterior pituitary. In the male, LH also
stimulates the release of testosterone which, decreases GnRH pulses and promotes growth of muscle,
bone and secondary sex organs. [1][3].
FSH is essential for the proper reproductive development in both sexes. In males, follitropin
promotes spermatogenesis and stimulates primary spermatocytes to undergo meiosis. In females, FSH
is crucial for developing and sustaining ovarian foll icles through the activation of over 100 different
genes, all of which leads to multiple physical changes such as increased vascularization of the theca
interna layer of cells near the basal lamina and formation of a fluid-filled antrum within the growing
follicular cell [1]. FSH effectively prepares the uterus for implantation of a fertilized egg [2]. As levels
of inhibin increase, FSH levels decrease and remain low until the end of the luteal phase, the latter
stage of menstruation, in which a renewed, steady rise in FSH prepares more follicular cells for the
next ovulatory cycle [2][3].
Oral contraception works by interrupting the FSH signaling pathway: the pills contain estrogen
and/or progesterone. As mentioned above, high levels of progesterone negatively feeds back on the
hypothalamus, causing a decrease in the amount of gonadotropin releasing hormone (GnRH), which in

turn results in a decrease in the release of FSH and LH by the anterior pituitary. Also, high levels of
estrogen negatively feeds back on the anterior pituitary gland and inhibit the release of FSH [3]. The
presence of oral contraceptives thus prevents proper reproductive maturation by inhibiting the release
of FSH and LH, which cause the ovary cells to undergo atresia and therefore suppress the chance of
successful ovulation [4].
However, studies have shown that inducing unnaturally elevated levels of estrogen and
progesterone by consuming these pills have dangerous side effects. For example, a 2010 paper
published in the Expert Review of Cardiovascular Therapy journal showed that usage of the combined
hormonal oral contraceptive had significant correlations with an increased risk in venous
thromboembolism, which is the formation of blood clots in veins, commonly in the leg or pelvic area
[4]. A meta-analysis of several studies have shown similar results in that women taking second
generation oral contraceptives (containing less than 50 ȝg of estrogen) have a significantly higher risk
of both myocardial infarction and ischemic stroke. Third generation contraceptives are associated with
a high risk of vascular arterial complications, especially with women of older age [5]. Additional
research supports the conclusion that usage of certain oral contraceptives (such as desogestrel and
gestodene) is associated with higher risk of ischemic stroke, deep vein thrombosis and cardiovascular
disease [6]. However, it is not just the cardiovascular system that is impacted negatively by the
consumption of oral contraceptives. An in-depth study has revealed that both perimenopausal and
postmenopausal women who take oral contraceptives on a chronic basis increases their risks of breast,
cervical and liver cancer in addition to ischemic stroke. The risk was observed to be greater when the
women took the combined estrogen-progesterone pills as compared to estrogen alone. However, the
same study showed that there can also be multiple beneficial side effects, such as decreased risk of
ovarian and endometrial cancer, pelvic inflammatory disease (PID) and colorectal cancer [7]. Another
study showed that high levels of estrogen sustained for over 21 days lead to abnormally high levels of
plasma cortisol and tryptophan, as well as high levels of tryptophan metabolites in urine. The

researchers suggest that these elevated tryptophan levels may be related to mental depression and/or
rheumatoid arthritis, though the mechanisms remain uncertain. They also postulate that the higher
cortisol levels as a result of the oral contraceptive pills led to the liver being exposed to high
glucocorticoid concentrations, which led to the finding of impaired glucose tolerance in 75% of the
women, while 13% developed diabetes mellitus [8]. Finally, one comprehensive study provides
evidence that estrogen/progesterone pills have little to no effect on the risk of developing breast cancer,
contradictory to what other studies have shown [9]. Clearly, these pills have an intricate and complex
range of effects on the human body, much of which is not completely understood.
Another possible contraceptive option is called the intrauterine device (IUD), which works by
inserting a T-shaped object into the uterus, inducing a localized inflammatory reaction in the
endometrium, causing a release of the of endometrium's cellular and humoral components.
Additionally, some IUD's, such as Cu-IUD's, release ions such as copper into the uterine cavity, which
can reach concentrations toxic to sperm and/or developing zygotes [10]. IUD's have higher success
rates for preventing pregnancy than do hormonal pills, but have also been known to cause heavier
bleeding or more painful menstrual cramps [3][3.5]. There is one possible method of contraception that
has not been explored, but may have a high chance of success without harmful side effects, and that is
blocking the FSHR directly.
The FSHR belongs to a class of large molecules called G-protein coupled receptors which are
embedded in the cell membrane. They have a 7-alpha helical transmembrane spanning domain (TM
domain) and a glycosylated extracellular domain (ECD). They are highly prolific in mammal granulosa
cells: those from rats are reported to have around 4,600 receptors per cell. It is worthy to note here that
this protein, in particular the TM domain, is highly conserved among animal species, especially
mammals, with the most variation in the C-terminal tail [1]. Glycosylation of the ECD is also highly
conserved. Thus, research done on rat FSHR is highly applicable to human FSHR. Binding of FSH to
the ECD of the receptor causes a shift in conformation and activation of the G-protein at the C-

terminus on the intracellular side of the membrane. This action causes adenlyl cyclase to convert ATP
to cAMP, beginning a very complex protein signaling pathway illustrated in Figure 1 that eventually
leads to gene expression [2]. An important step in the signaling pathway is the activation of protein
kinase A (PKA), a necessary action for the directing of granulosa cell differentiation, as signals from
cAMP are mainly mediated through PKA. For example, PKA regulates the activity of the transcription
factor cAMP response element binding protein (CREB) and protein kinase p38 MAPK, two different
signaling pathways that contribute to follicular maturation. As can be seen on Figure 1, there is another
signaling pathway that is activated by calcium ion movement (with some unknown protein regulating
that activity) rather than by FSH binding. However, even this pathway is eventually influenced by
FSHR activity, as one of its proteins, PTP/ERK, is phosphorylated by PKA [2]. The importance of the
FSHR in proper reproductive development is further shown by the low occurrences of natural
mutations, as such errors would result in lower fertility and inability of the organism to pass down the
mutated genes. This is evidenced by the A172V mutation in the ECD domain, something found among
a sub-population in Finland, associated with hypergonadotropic ovarian dysgenesis. Many victims
presented with infertily, amenorrhea, stunted follicular maturation, and variable secondary sex
characteristics [11]. Therefore, it is reasonable to conclude that if a female were to use a form of
contraception that blocked FSH binding to its receptor, the follicles would be unable to mature properly
and ovulate.

Figure 1. The protein signaling pathways found in human ovary granulosa cells. FSH plays a major role in regulating these
pathways. Taken from Hunzicker-Dunn and Miazels (2006).

However, it is important to note a major drawback to this strategy. Though blocking the FSHR
may prove to be an effective method of preventing pregnancy, it also causes a decrease or even a halt in
the production of estrogen, which is important for many others functions in addition to reproductive
ones, as mentioned earlier [2]. In order to have normal physiological growth and function while taking
this form of birth control, the female would need to take estrogen supplements, which is essentially the
same issue with consuming oral contraceptives. However, it is possible that blocking the FSHR can
function as a safe form of male birth control. Blocking the FSHR in males will decrease
spermatogensis, but will not affect testosterone production and secretion, as that is regulated by LH

binding [2]. This allows for normal, healthy growth in the male while stunting fertility.
Another possible area of interest concerning the blocking of FSHR is animal sterilization. The
Michaelson Prize & Grants Foundation offers a $25 million prize for the first, one-shot non-surgical
sterilization of cats and dogs, in order to combat the high rates of euthanasia found in pet shelters
countrywide [12]. As mentioned earlier, the FSHR is a highly conserved protein, and this fact holds
true between humans, cats and dogs [Figure 2]. 88.33% of the amino acids in the extracellular region of
the FSHR protein are exactly the same between the three species, and only 3.06% are completely
different [Table 1]. Blocking the FSHR with a molecule that was specifically toxic to the reproductive
cells it was binding to holds potential as a possible one-shot, chemical sterilization. Thus we propose
the usage of aptamers as a novel substitute for traditional oral contraceptives and as a potential
sterilization technique in cats and dogs.
Table 1. A quantified comparison of the amino acid similarities and dissimilarities between human, cat and dog FSHR (360
amino acid long extracellular region). “Identity” indicates amino acids that are exactly the same between the three species.

Number of Amino Acids

Percentage (%)

Identity

318

88.33

Strongly Similar

28

7.78

Weakly Similar

3

0.83

Different

11

3.06

Figure 2. The sequences for the cat, dog, and human FSHR protein (specifically the 360 amino acid long extracellular
binding domain). An asterik (*) indicates an exact match between the three species', a colon (:) indicates strong similarity, a
period (.) indicates weak similarity and absence of a mark indicates a major amino acid difference.

Nucleic acids (namely, RNA and DNA) have generally been associated with the storage of
genetic information. However, their ability to form complex three-dimensional structures have raised
interesting possibilities, as this causes the oligonucleotides to exhibit specific intermolecular forces that

may bind to a ligand of interest, such as an enzyme's catalytic domain. They have the potential of
becoming very important tools in the science of molecular recognition, a field in which antibodies have
long held reign, since before the 1950's [13]. However, the usage of aptamers offers several advantages
over the usage of antibodies as molecular sensing probes. Because the aptamer selection process is
done in vitro, researchers have much greater control over the non-physiological conditions that can be
used to strengthen their binding, such as salt concentration, pH, and temperature. Antibodies require an
animal host, which in itself presents greater difficulties as the molecule of interest may be toxic to the
organism or have little inherent immunogenic response [13][14]. Additionally, they are much more
stable than antibodies due to the rigidity of the phosphodiester backbone. High temperatures, harsh pH
conditions or drastically high levels of salt would irreversibly denature antibody proteins, while a RNA
or DNA aptamer would merely unfold temporarily. In fact, because antibody markers can only be
produced in vivo, they are restricted to physiological conditions, which means the kinetic parameters of
their interactions with target molecules cannot be modified. Finally, due to the protein nature of
antibodies, they cannot be stored for a long time, as they will gradually degrade. On the other hand,
aptamers have a longer shelf life, as oligonucleotide structures tend to be very stable [11][12].

The in vitro method of selection used to make specific aptamers is called the systematic
evolution of ligands by exponential enrichment (SELEX), as illustrated in Figure 3 [15]. It begins with
the synthesis of a vast library of oligonucleotides (RNA, ssDNA, or dsDNA) that have randomized
sequences with fixed ends for primer binding during PCR amplification. After PCR, transcription may
be done to get RNA back, if necessary. These oligonucleotides are then incubated with the target
molecules. Some of these randomized strands will have a greater affinity for binding than others due to
the specific Watson-Crick pairing, non-standard base pairing and novel interactions due to unique three
dimensional structures, such as clover shapes and loops and bent “lollipops”[15][16][18]. The more
strongly bound oligonucleotides are isolated and amplified by PCR. These eluted molecules are subject
to several more rounds of binding under more stringent conditions, such as increased wash time, higher
pH, or higher temperature. The oligonucleotides that remain after multiple cycles bind very strongly to

the target ligand. They are then isolated, cloned and analyzed [15].

Figure 3. The SELEX process as shown in a flowchart form. Taken from Nieuwlandt (2000).

There exists a more specific form of aptamer selection called cell-SELEX that targets entire
cells or ligands bound to cells as opposed to free-floating molecules. The procedure is very similar to
normal SELEX, though often with the additional step of counter-selection. As shown in Figure 4, cellSELEX starts in the expected fashion: a randomized oligonucleotide library is incubated with the target
cells, and the bound oligonucleotides are eluted [16]. At this point, the researcher employs the counterselection technique, in which the eluted molecules are incubated with non-target cells (referred to as
negative cells), after which the supernatant containing unbound oligonucleotides is collected and the
bound aptamer-negative cells are discarded. The unbound oligonucleotides are then amplified by PCR
and go through the selection process again, with more stringent measures [16].

Figure 4. Cell-SELEX, with counter-selection done against negative cells. Taken from Guo et al. (2008).

Counter-selection serves to eliminate aptamer candidates that may bind to cells other than the
target; thus, aptamers that bind less specifically. This has been shown to be especially useful in the field

of cancer research. Researchers incubated the oligonucleotide library with a cultured precursor T cell
acute lymphoblastic leukemia (ALL) cell line, called CCRF-CEM, while using a B-cell line from
human Burkitt's lymphoma called Ramos as the counter-selection [16]. This allowed the researchers to
select for aptamers that bound much more specifically to CCRF-CEM as opposed to the Ramos cells,
which shares several cell surface ligands. In this way, aptamers can be very useful in discovering
cancer-specific bio-markers and cell-surface epitopes, which would allow physicians to target and
destroy cancer cells specifically, as opposed to current treatments that put somatic cells (that are similar
to the cancer cells) at risk [16][17][18]. Aptamers have also shown great potential in early cancer
detection. Current methods that attempt to detect specific types of cancer lines have been met with
great difficulty due to a low density of cell surface targets for binding. Aptamers conjugated with
nanoparticles such as Au-Ag nanorods show much greater efficacy in binding to the cancer cells
specifically, as the aptamer-nanorod complexes did not bind to non-target cells [16]. Aptamers can also
be conjugated with magnetic and fluorescent nanoparticles (MNP and FNP, respectively), which makes
it even easier to detect and diagnose the presence of the target cells. These bioconjugates have the
potential to greatly aid drug delivery, as current chemotherapies often result in death of both healthy
and cancerous cells [17]. Lastly, aptamers are useful in biological system not only because of their
specific binding (which reduces the chance of side effect toxicity), but also because they have relatively
short half-lives (due to organic nuclease activity) and are quickly cleared out of the bloodstream by
kidneys. Certain modifications such as polyethylene glycol linkage can increase the half-live up to a
week [17].
In our research, we expect to develop an aptamer that binds specifically to the hFSHR in vitro
using a modified version of the standard cell-SELEX procedure. We will perform the counter-selection
first, using human embryonic kidney cells (HEK293) provided by James A. Dias from the University of
Albany. We will then discard the cells and their bound aptamers, and collect the remaining unbound
oligonucleotides and incubate them with hFSHR-transfected HEK293 cells (henceforth referred to as

HEK293r's). These oligonucleotides will only bind the FSHR, as they have already been counterselected against the other ligands present on the HEK293r cells. Afterward, the bound oligonucleotides
will be eluted and amplified and subject to more rounds of selections, with increasing stringency.
Producing aptamers that bind very specifically to the hFSHR will inhibit the natural hormone
from binding, which we hypothesize will stunt follicular development, thus acting as a form of oral
contraception, most likely for males. . This is a novel project that will open the door to a new, safer and
possibly more cost-effective form of contraception that does not introduce extra hormones into the
human body. It also holds potential as a sterilization method for cats and dogs, which would reduce
euthanasia rates in pet shelters.
Materials and Methods
RNA pool. We purchased our pool of random oligonucleotides from Integrated DNA Technologies, Inc.
The total pool contained 100 nmol of ssDNA, which we aliquoted and diluted to several samples that
HDFKKDGDFRQFHQWUDWLRQRISPȝ/(DFKROLJRQXFOHRWLGHVHJPHQWwas 77 bases in length, with a
randomized 40 base region in the center. The outer 5' and 3' regions were kept constant in order to bind
to T7-XbaI and Rev-HinDIII flanking PCR primers, respectively. The sequence for our primers and
oligonucleotide were obtained from Bouvet's protocol, and are shown below [17]:
Table 2. The sequences for both primers and oligonucleotide molecules we used.
Nucleic acid strand
Sequence
T7-XbaI flanking primer

3’-TTA CAG CAA CCA CCG GG GAT ATC ACT CAG CAT AAT CCT AGG CGC-5’

Rev-HinDIII flanking primer

5’-CCC GAC ACC CGC GGA TCC ATG GGC ACT ATT TAT ATC AAC-3'

Oligonucleotide

5'-TGGGCACTATTTATATCAAC(N40)AATGTCGTTGGTGGCCC-3'

After PCR amplification, we converted our dsDNA pool into an ssRNA pool via transcription.

PCR3&5UHDFWLRQVFRQWDLQHGSP'1$WHPSODWHȝ/5HYIODQNLQJSULPHUȝ/7IODQNLQJ
SULPHUȝ/7DTEXIIHUȝ/7DTSRO\PHUDVHDQGȝ/G173 V7KHWRWDOYROXPHZDVȝ/7KHUPDl

cycling began with one cycle at 95°C for one minute , 25 repeating cycles at 94°C for one minute, 50°C
for one minute, and 72°C for one minute, followed by a cycle at 72°C for ten minutes. After PCR, the
presence of product was confirmed by 3% agarose geO ȝ/(WKLGLXP%URPLGHDGGHG DQGWKHQ
subsequently purified by phenol/chloroform extraction and ethanol precipitation.

Cell-SELEX. 135-ȝ/RIVV51$ZDVILUVWKHDWHGDW&IRUPLQXWHVDQGWKHQLPPHGLDWHO\SXWRQ
ice. Afterward, they were incubated with HEK-293 cells with transfected hFSHR (or with untransfected
cells if counter-selection was being performed) for 45 minutes at different temperatures (starting at
4°C) depending on stringency level. At room temperature and above, RNAse inhibitor was also
employed. Cells were vigorously vortexed and triterated to increase surface area for receptor binding. 1
mL of binding buffer was also added. After selection, centrifugation was done at 13,000 RPM for five
minutes and the supernatant was discarded. 7KHFHOOVZHUHWKHQYRUWH[HGZLWKȝ/RIZDVKEXIIHU
and heated again at 95°C for five minutes to elute the bound oligonuceotides. Centrifugation was then
done once more under the same conditions, and the supernatant was collected and a phenol/chloroform
extraction was performed. Afterward, reverse transcription and PCR amplification were done to
ascertain the presence of product.

Wash buffer and binding buffer. The wash buffer solution was composed of 450 mg glucose, 10 mL 10x
PBS buffer, 5 mM MgCl2 and 90 mL of nanopure water. The binding buffer was created using 10 mL
of wash buffer and 10 mg of Bovine Serum Albumin (BSA).

Transcription and reverse transcription. Transcription was done using a HiScribeTM T7 in vitro
transcription kit, specifically: ȝ/GV'1$WHPSODWHȝ/WUDQVFULSWLRQEXIIHUȝ/$73DQGȝ/
*73IURP1HZ(QJODQG%LRODEV 1(% ȝ/ -Fluoro-&73DQGȝ/ -Fluoro-UTP from TriLink
%LRWHFKQRORJLHVȝ/[KLJKPROHFXODUZHLJKW +0: PL[DQGȝ/751$SRO\PHUDVH

Reverse transcription was done using a Quanta Biosciences, Inc. qScriptTM cDNA synthesis kit,
VSHFLILFDOO\ȝ/RI51$ȝ/RI51$DVH-IUHHZDWHUȝ/PL[ UHYHUVHWUDQVFULSWLRQEXIIHU
QHFHVVDU\SULPHUV DQGȝ/RIUHYHUVHWUDQVFULSWDVH
Results
For the counter-selection, the random oligonucleotide pool was incubated with wild-type HEK-293
cells. The supernatant RNA was then enriched via reverse transcription and PCR, and a band estimated
to be about 123 base pairs was obtained, as shown in lane 2 (Figure 5a), indicating a successful
recovery of RNA that did not bind to the wild-type cells. This band presented itself again after the first
round of positive selection with HEK-293R cells, which also occurred at 4oC (Figure 5b), representing
the fraction of our oligonucleotide pool that binds to the FSHR containing cells at 4oC. This band,
however, was absent in the gel after the second round of selection (at 22oC), as shown in Figures 5c and
5d. Only after the addition of an RNAse inhibitor did this band appear again (Figure 5e), which
indicates that RNA was now being successfully eluted from FSHR proteins at 22oC.
The nanodrop experiment (Figure 6) done on this current oligonucleotide pool showed that
there was a concentration of 55.2 ng/uL of RNA suspended in the solution. The nanodrop experiments
(Figures 7 and 8) done on both RNA incubated with both normal type HEK293 cells and FSHR
transfected HEK-293 cells yielded concentrations of 154.1 ng/uL and 100.8 ng/uL, respectively.
Selection was carried out at 30oC, but the 135 base pair band was absent again (Figure 5f), even
with the addition of the RNAse inhibitor.

Figure 5. Gels showing results after counter-selection (5a), SELEX at 4oC (5b), SELEX at 22oC (5c-e), and SELEX at 30oC
(5f). DNA molecular weight markers are in the first lane, and the product band in the second lane.

Figure 6. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the oligonucleotide pool.

Figure 7. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the HEK-293 cells.

Figure 8. Nanodrop experiment showing the absorbance of RNA at 230 nanometers (nm) for the HEK-293r cells.

Discussion
Using Cell-SELEX, we have been able to select for a group of oligonucleotides that bind to the hFSHR
at room temperature. The presence of these oligonucleotides has been determined by both gel
electrophoresis of the PCR product after reverse transcription of our RNA and by the nanodrop

experiment. The latter shows a lower concentration of RNA when incubated with the HEK-293r cells,
indicating that some portion of the oligonucleotides are binding effectively to the FSH receptor, though
more experimentation needs to be done to quantify the level of binding.
Each RNA molecule in our current pool is 123 bases long, though we started from a pool in
which the the oligonucleotides were 77 bases long (consisting of two flanking constant regions for
primer binding during PCR that are 17 (3' end) and 20 (5' end) bases each and a middle randomized 40
base region). This increase in RNA molecule length is due to the nature of the flanking primers we
used, as according to Bouvet's protocol [19]: the T7 flanking primer, binding to the 3' end of our
oligonucleotides, is 39 bases long, and the Rev flanking primer, binding to the 5' end, is 44 bases long,
as can be seen in Table 2. After PCR amplification, this results in an RNA oligonucleotide pool that is
46 bases longer than the original pool.
Longer constant regions may encourage new, stronger forms of binding, as the molecules have
more opportunity for different forms of 3-dimensional binding, such as larger stem loops or three way
junctions. However, the fact that primers are longer than the constant regions of the parent
oligonucleotides mean that there are several nucleotides on both primers that do not bind predictably to
any present sequence (19 and 27 on the T7 and Rev flanking primers, respectively). There is a
possibility that parts of these 'extra' sequences may bind to parts of the randomized 40-mer region,
masking that sequence's accessibility to binding to the FSHR. This may result in the loss of some
potential aptamer candidates.
The actual values for the concentration of RNA for the nanodrop experiments are also important
to address. Incubating the oligonucleotides with wild-type HEK293 cells showed a concentration of
RNA that was 53.2 ng/uL greater than that of the RNA incubating with HEK293r cells, which shows
some degree of specific binding to hFSHR. However, both concentrations are over 100 ng/uL, a
seemingly impossible value when we consider that the nanodrop experiment of just our RNA pool
showed a concentration of 55.2 ng/uL. We expected that the nanodrop of the RNA incubating with the

wild type HEK293 cells would have showed a concentration equal to or slightly less than that of the
nanodrop experiment of the RNA pool (as some of the oligonucleotides may still be binding to the
molecules on the surface of the HEK293 cells). As for the RNA incubating with HEK293r cells, we
expected a lower concentration than 55.2 ng/uL, if they were binding more specifically to the
transfected hFSHR proteins.
We can begin to explain this paradoxical situation by using the simple fact that HEK293 have
their own native RNA molecules. The cells would have been somewhat lysed from the beginning of the
incubation due to the method of storage. Being frozen in water and stored in a -20oC freezer would
cause ice crystals to form and puncture the cells. Next, to thoroughly incubate the cells with the RNA
pool in a way that increased potential receptor-oligonucleotide interaction, the cells were triterated and
vortexed, causing further strain and breakage. This will lead to the cell's native RNA's to be expelled
into the solution that contains our aptamer candidates. The nanodrop machine cannot distinguish
between the two different groups of RNA and this likely resulted in the much larger reported
concentration of RNA than expected.
In the future, this part of our research can be improved by changing the procedure by which the
nanodrop experiment is done: instead of using deionized water as the control, we should use the
solution surrounding HEK293 cells. In other words, in addition to incubating the RNA pool with
HEK293 and HEK293r cells, a third tube should have only HEK293 without our oligonucleotide
molecules present. All other treatments should remain the same: the cells will be triterated and vortexed
and left at room temperature for 45 minutes. Theoretically, the native RNA molecules will come out
just the same. If this solution were used as the control, the HEK293's RNA should be subtracted out
when the nanodrop experiment is done on the other two solutions, and our aptamer candidates should
be the only RNA molecules for which the nanodrop experiment reports the concentration.
In addition to the native RNA, riboncleases (RNAses) are released upon cell lysis. These
molecules are used by all organisms to catalyze RNA degradation, a process that is crucial if the parent

RNA is no longer required or if the smaller metabolites are to be used in new molecular pathways [20].
There are many types of RNAses, some of which are not particularly specific. This helps the cell target
foreign RNA molecules, such as viral injected RNA, and inactivate them.
This situation presented itself as a problem in our experiment: our aptamer candidates are
essentially foreign RNA molecules. At 22oC, we could not recover our RNA molecules after the
SELEX process, and it is most likely due to the presence of RNAse molecules that emerged from the
lysed HEK293 cells (Figures 5c and 5d). We put this hypothesis to the test by running another SELEX
experiment at 22oC, this time adding an RNAse inhibitor, a molecule that binds to RNAse molecules in
order to prevent RNA degradation. As can be seen in Figure 5e, this allowed us to recover
oligonucleotides after the SELEX process. At 4oC, the SELEX process went to completion, even
without the use of the RNAse inhibitor [Figure 5b]. The lower temperature neatly explains this
phenomenon: most enzymes, such as ribonucleases, are active at certain temperature ranges, and 4oC is
too low for activation of RNAses.
However, even with the presence of the inhibitor, the SELEX did not work at 30oC; The
expected 134 base pair band was absent from the subsequent gel (Figure 5f). As all other conditions in
this experimental run were identical to that in the 22oC run, the change in temperature must be the main
factor that is contributing to the loss of product. Logically, there are three major ways the increased
temperature may affect the experiment: it may be reducing the efficacy of the RNAse inhibitor, it may
be affecting the structure of the oligonucleotides, or it may be inhibiting the binding between the RNA
molecules and the hFSHR protein.
The RNAse inhibitor that we used was a 50 kDa water-soluble protein derived from rat lung,
whose recombinant product is produced in E. coli (Roche®) [21]. At higher temperatures, proteins will
begin to denature and lose their specific tertiary structure, which leads to inhibition or loss of regular
function. Our RNAse inhibitor protein is reported to have an active temperature range of 25°C – 55°C,
and still retain partial activity at 60°C [21]. Our last SELEX procedure was done at 30°C, which is well

within the active temperature range for our inhibitor, thus eliminating the possibility of enzyme
degradation as an explanation for the lack of binding oligonucleotides.
Our RNA molecules form specific three-dimensional shapes via both Watson-Crick and nonstandard hydrogen bonding (such as Hoogstein base pairing) between the bases on its own sequence.
Heat definitely affects the strength of this binding, as melting curves have been analyzed for both RNA
and DNA, in order to the determine the point at which the hydrogen bonds break and the sequence
denatures. These studies cast doubt on the idea that increasing the temperature of our SELEX
procedure from 22°C to 30°C is causing changes in the structures of our RNA oligonucleotides, as
30°C is not a high enough temperature to truly affect the strength of base pairing. Research done has
shown that tRNA, which is similar to our aptamer candidates in that it is a single stranded RNA chain
base paired to itself, have melting ranges between 50oC and 75oC, depending on various factors, such
as: ion concentrations, GC content, length of the RNA sequence and specific 3-dimensional structure
(number, size and length of loops) [22][23]. At some point in the melting curve, there is usually a
sudden, sharp increase in denatured RNA. This sharp slope indicates that there is a fast transition
between between stable and denatured RNA, and that the heat is not slowly altering the 3-dimensional
structure throughout the process. Also, tRNA molecules are generally between 70-95 bases long, and
our oligonucleotides are 134 bases long; a longer chain leads to more stability through an increased
number of hydrogen bonding[22]. So it may be concluded that our SELEX at 30°C is not altering the
actual structure of the oligonucleotides.
Receptor-drug interactions are sensitive to small changes in the environment, such as pH,
solubility, and temperature. Another possibility for the lack of binding in our latest SELEX may be that
increasing the temperature from 22°C to 30°C is affecting the binding of our oligonucleotides to the
hFSHR binding site in some unfavorable way. However, the hFSHR binds to its natural ligand, FSH, at
human body temperature, which is 37°C. We have shown experimentally that our oligonucleotides bind
at 22°C, so it seems unlikely that the binding interaction would be stunted at 30°C but then at 37°C,

occur readily. One explanation is that our RNA molecules bind less strongly to the active site than the
natural ligand. Experimentation must be done to ascertain the binding strengths of our current
oligonucleotides to the hFSHR and compare it to that between FSH and the hFSHR.
Additionally, it is possible that our oligonucleotides are not binding to the active site at all;
perhaps they are binding allosterically, or as an umbrella agonist/antagonist [24]. That is also a question
that remains to be answered: we do not know the exact nature of the oligonucleotide-protein binding.
There are many facets to consider: agonism versus antagonism of the hFSHR, the strength of binding (a
partial antagonist may end up competing with FSH in binding to the receptor) and the location of
interaction. Our RNA molecules may be binding allosterically or as umbrella agonist/antagonist.
After we succeed in using our cell-SELEX procedure to produce a pool of RNA that binds
effectively at 37°C, the next course of action will be to quantitatively determine the strength and nature
of binding. We will also need to determine the exact sequences of our best aptamers. Our long term
future goals are to start in vivo trials of our aptamers in models model organisms whose FSH receptor
protein is best conserved as compared to humans. Eventually, we can begin a SELEX process
specifically for cat or dog FSHR (or other important reproductive proteins). At present, there are still
many questions that need to be answered, and much research needs to be done.
Annotated Bibliography
1. Dias, J.A., Cohen, B.D., Lindau-Shepard, B., Nechamen, C.A., Peterson, A.J., Schmidt, A. 2002.
Molecular, structural, and cellular biology of follitropin and follitropin receptor. Vitamins &
Hormones. 64:249-322.
This is a very in-depth study of the human follicle stimulating hormone receptor that gives details about
the structure and function of this protein in the human body. I used the information in this paper to help
give background information for this receptor protein, in order to highlight its importance in scientific
research and why I am interesting in studying it.
2. Hunzicker-Dunn, M., Miazels, E.T. 2006. FSH signaling pathways in immature granulosa cells that
regulate target gene expression: branching out from protein kinase A. Cellular Signaling.
18(9):1351-9.
This article supplements Dias et. al.'s paper in that it offers additional information about the structure
and function of the human follicle stimulating hormone receptor, in particular details pertaining to the

proteins involved in its signaling pathways.
3. Speroff, L., Darney, P. D. 2005. "Oral Contraception". A Clinical Guide for Contraception (4th
ed.). Philadelphia: Lippincott Williams & Wilkins.
Speroff and Darney's book provides ample information regarding the mechanism by which medically
prescribed oral contraceptives work: specifically, the pathways of the estrogen and progesterone in the
pills, and how they cause negative feedback loops that ultimately result in inhibition of FSH release
and prevent ovulation. Furthermore, this book provides information about other forms of contraception
such as intrauterine devices (IUD's).
4. Blanco-Molina, A., Monreal, M. 2010. Venous thromboembolism in women taking hormonal
contraceptives. Expert review of cardiovascular therapy. 8(2): 211–5
This is the first of several papers that I used to elucidate upon medical issues related to taking hormonal
contraceptives. Blanco-Molina and Monreal's paper specifically addresses the risk and occurrence of
venous thromboembolisms, which are blood clots forming in the veins, in response to the
contraceptives.
5. Baillargeon, J., McClish, D.K., Essah, P.A., Nestler, J.E. 2005. Association between the Current Use
of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: A Meta-Analysis. Journal of
Clinical Endocrinology & Metabolism. 90(7): 3863–3870.
The results of this paper show that there is an increased risk of cardiovascular disease with chronic
usage of oral contraceptives, especially in older groups.
6. Kemmeren, J.M., Tanis, B.C., van den Bosch, M.A.A.J., Bollen, E., Helmerhorst, F.M. van der
Graaf, Y., Rosendaal F.R., and Ale Algra. 2002. Risk of Arterial Thrombosis in Relation to Oral
Contraceptives (RATIO) Study: Oral Contraceptives and the Risk of Ischemic Stroke. Stroke
(American Heart Association, Inc.) 33(5): 1202–1208
This extensive study looked at the association between oral contraceptives and risk of arterial
thrombosis and ischemic stroke, both of which are usually rarely found in young women. Scientists
have found that both diseases seem occur at increased frequency in populations of young women who
ingest the contraceptives.
7. Combined Estrogen-Progestogen Contraceptives. 2007. IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans (International Agency for Research on Cancer).
This is a very interesting and thorough study of the effect of oral contraceptives on cardiovascular
disease and multiple types of cancer. They write that there is “sufficient evidence” to suggest that
estrogen-progesterone pills increase the risk of breast, cervical and liver cancer. However, they also
found that the same pills helps reduce the the risk of ovarian and endometrial cancer and pelvic
inflammatory disease (PID).
8. Rose, D.P., Adams, P.W. 1972. Oral contraceptives and tryptophan metabolism: effects of
oestrogen in low dose combined with a progestagen and of a low-dose progestagen (megestrol
acetate) given alone. Journal of Clinical Pathology. 25(3): 252–8.

Rose and Adams observed that 21 days upon ingestion of the oral contraceptives, serum tryptophan
levels were raised to abnormal levels. Additionally, they found elevated levels of tryptophan
metabolites in the urine of the subjects. They also observed changes in the way the subjects' somatic
cells absorbed glocuse: 75% of the women taking the medicine had impaired glucose tolerance, and
13% developed chemical diabetes mellitus.
9. Collaborative Group on Hormonal Factors in Breast Cancer. 1996. Breast cancer and hormonal
contraceptives: further results. Contraception. 54(3 Suppl): 1S–106S.
This comprehensive study ultimately found that oral contraceptives have little or no effect on the risk
of breast cancer in women, a find that clashes with the data of other studies. Additionally, they found
that there is very little difference in the effects of specific types of estrogen and progesterone in the
pills.
10. Ortiz, M. E., Croxatto, H. B., & Bardin, C. W. 1996. Mechanisms of action of intrauterine devices.
Obstetrical & gynecological survey, 51(12), 42S-51S.
This paper discusses the mechanism by which intrauterine devices (IUD's) work in order to prevent
fertilization and pregnancy.
11. Aittomäki, K., Dieguez-Lucena, J., Pakarinen, P., Sistonen, P., Tapanainen, J., Gromoll, J.,
Kaskikari, R., Sanika, E.M., Lehvaslaiho, H., Engel, A.R., Nieschlag, E., Huhtaniemi, I., de la
Chapelle, A. 1995. Mutation in the follicle-stimulating hormone receptor gene causes hereditary
hypergonadotropic ovarian failure. Cell, 82(6), 959-968.
This study showed that mutations in the human FSHR protein may produce very serious medical
complications, particularly relating to reproduction, indicating the importance of this protein in
reproduction.
12. "Michelson Prize." Found Animals Foundation. 12 June 2013.
<http://michelson.foundanimals.org/michelson-prize>
This is the website for the Michelson Prize & Grants foundation, which offers both grants for research
on a safe one-shot, non-surgical sterilization of cats and dogs and a $25 million prize for the first to
achieve in finding the the technique.
13. Jayasena, S.D. 1999. Aptamers: An Emerging Class of Molecules That Rival Antibodies in
Diagnostics. Clinical Chemistry. 45(9):1628-1650.
Jayasena's paper delves into the details of why using an RNA or DNA aptamer may be more
advantageous than using an antibody as a binding, targeting or marking molecule; for example,
aptamers do not raise an immune response as easily, longer shelf lives and the ability to regenerate after
denaturation.
14. McKeague, M., & DeRosa, M. C. (2012). Challenges and opportunities for small molecule aptamer
development. Journal of nucleic acids, 2012.
This paper further discusses the usage of RNA and DNA molecules as superior bio-sensors and in
binding to specific targets, as compared to the traditional antibody.

15. Nieuwlandt, D. 2000. In vitro selection of functional nucleic acid sequences. Current Issues in
Molecular Biology. 2(1):9-16.
This paper describes SELEX, the in vitro process by which you select the oligonucleotide sequence
(out of your random pool) that binds most specifically to your target molecule. This study highlights
different selection methods, the process of increasing selection stringency and amplifying the
oligonucleotides that could be your target aptamers. This study stresses the idea that as we learn more
and more about the three dimensional structure of nucleic acid chains affect their function, we begin to
realize the importance of these aptamers as potential research tools (such as for drug design).
16. Guo, K.T., Ziemer, G., Paul, A., Wendel, H.P. 2008. CELL-SELEX: Novel perspectives of aptamerbased therapeutics. Int J Mol Sci. 9(4):668-78.
This paper gives a broad yet descriptive overview of the process of aptamer binding to both specific,
isolated proteins and whole cells, giving many examples of the clinical significance of this research,
such as cancer therapy and gene silencing. Essentially, this paper provides a lot of backbone
information that explains the growing importance of aptamers in biomedical research.
17. Fang, X., Tan, W. 2010. Aptamers Generated from Cell-SELEX for Molecular Medicine: A
Chemical Biology Approach. Acc Chem Res. 43(1): 48-57.
This paper provides further information about producing aptamers that could be used to target entire
cells. They used the process of Cell-SELEX (which they outline in a diagram as well) to target cancer
cells and they report positive results. However, cancer cells do not have many target molecules on their
surface during the early stages for aptamers to bind to, so they tested the efficacy of aptamer-nanoparticle complexes, as they bind multivalently to cell surfaces. Their data shows promising results for
the ability of aptamers to bind very specifically to cells and one day to be used in chemotherapy.
18. Graham, J.C., Zarbl, H. 2012. Use of Cell-SELEX to Generate DNA Aptamers as Molecular Probes
of HPV-Associated Cervical Cancer Cells. PLoS One. 7(4): e36103. 1-9.
These scientists also employed Cell-SELEX for targeting a specific strain of cervical cancer cells,
showing that aptamers can be used as efficient bio-markers, an important tool in the field of clinical
research. As I will be performing SELEX with whole HEK293 cells, the methods and materials
provided in this paper will be very helpful as I set up my own experiments.
19. Bouvet, P. 2009. Identification of nucleic acid high-affinity binding sequences of proteins by
SELEX. DNA-Protein Interactions (pp. 139-150). Humana Press.
We derived our aptamer selection and enrichment process from the protocol Phillip Bouvet published
in this book. We used the primers he used, as well as the same sequence for the outer constant regions
for our oligonucleotides.
20. D'Alessio, G., Riordan, J.F., eds. 1997. Ribonucleases: Structures and Functions, Academic Press.
This book provides a lot of information relating to ribonucleases and their structure and function in
cells and as a laboratory tool.

21. Roche® Diagnostics. Protector RNAse Inhibitor. April 2006. PDF file.
22. Beltchev, B., Yaneva, M., Staynov, D. 1976. Thermal Melting Curves of tRNAPhe from Yeast
Lacking Different Numbers of Nucleotides from the 3
European
End. Journal of Biochemistry,
64(2), 507-510.
This reference gives useful information how temperature affects the tructural integrity of tRNA
molecules, which are similar to our potential aptamer candidates in that both are single stranded RNA
molecules that fold 3-dimensionally upon themselves.
23. Yakovchuk, P., Protozanova, E., & Frank-Kamenetskii, M. D. (2006). Base-stacking and basepairing contributions into thermal stability of the DNA double helix. Nucleic acids research, 34(2),
564-574.
This paper talks about about how factors such as G-C content, base-stacking/pairing, and length of
sequence affects the thermal stability and melting point of DNA and other nucleotide seuqences.
24. Stevens, E. 2014. Medicinal Chemistry: The Modern Drug Discovery Process. Pearson Education,
Inc.
This textbook discusses different types of receptor binding, a crucial point to understand as we are not
sure how exactly our aptamers are binding to the FSHR protein.

